Syntimmune's Series A Round

Syntimmune raised a round of funding on October 24, 2014.

Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and repres…

Articles about Syntimmune's Series A Round: